Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Immunotherapy
  • Author : Kasuya Hideki
  • Release Date : 15 January 2021
  • Publisher : Academic Press
  • Genre : Science
  • Pages : 250
  • ISBN 13 : 0128229144

Download or read book entitled Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Immunotherapy written by Kasuya Hideki and published by Academic Press online. This book was released on 15 January 2021 with total pages 250. Available in PDF, EPUB and Kindle. Book excerpt: Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Immunotherapy discusses current treatment as well as treatment under investigation in pancreatic cancer. It brings information on how to combine current therapy with treatment under development and/or in clinical trials in order to be able to improve pancreatic cancer survival. Pancreatic cancer has a very low survival rate since it is discovered on late phase, when the patient already presents metastases and surgical options are limited. Currently, there are different modalities to treat pancreatic cancer, however its response has been poor and the toxicity of the treatment limits not only the survival rate, but also the patients that are able to get treated. This book reviews new modalities on basic research intending to reach the cure of pancreatic cancer, such as oncolytic viruses and Bi-specific T cell engager (BiTEs) as future clinical treatment, as well as discusses recent researches using those modalities as prospective combination therapy. The book is a valuable source for cancer researchers, oncologists and several members of medical and biomedical field who are interested in learning more about new therapies to treat pancreatic cancer. Reviews current situation of pancreatic cancer before discussing new modalities, so the reader gets knowledge on what it is available and on problems faced on its treatment currently Discusses oncolytic virus in pancreatic cancer use, mainly herpes and adenoviruses, the results obtained on basic research as well as in clinical trials Encompasses knowledge on Bi-specific T cell engager (BiTEs) focusing on its function, development and use on pancreatic cancer Brings information on combination therapies recently developed that allow lower dose of treatment, which means less side effect